Swifter market access for drugs will require a revolution
This article was originally published in Scrip
Executive Summary
The plenary session at the Drug Information Association’s Euromeeting in Monaco this week took the curious form of an enforced debate on pharmaceutical R&D productivity between representatives from the industry and regulatory authorities.